
Infectious diseases preclinical services



From microbes to One Health

VIBIOSPHEN is a French privately-owned and independent company specialized in infectious diseases. Vibiosphen offers R&D services to support **each step of the target product profile (TPP) definition**: from identifying the right indication and defining the *in vitro* efficacy of the product to proving the safety of the molecule and determining the dose or route of administration.



Sacteria

- Gram-negative and Gram positive ESKAPE – and more
- ATCC or clinical strains including resistant bacteria strains

Pathogens (non exhaustive)

🖗 Virus

- ✓ SARS-CoV-2
- ✓ Influenza H1N1
- Respiratory syncytial Virus
- Rhinovirus

₽9 11

ADDED VALUE

- BSL 2 and **BSL3 facilities** (to handle Mycobacterium tuberculosis, coronaviruses, certain chlamydia strains...)
- Quick turnaround time: 4 to 6 weeks between the acceptance of the proposal and the final results
- Custom model development
- Support and expertise to identify new indications, study plan design
- $\checkmark\,$ Availability, flexibility and reactivity of the team

Robin DUMAS, Business Developer Mobile : +337 827 276 23 Robin.dumas@vibiosphen.com Maxime FONTANIÉ, CEO Mobile : +336 501 553 97 Maxime.Fontanie@vibiosphen.com

Fungi

Candida

✓ Aspergillus

Trichophyton

Malassezia